Please check your internet connection and try again.
# Arsil dx
## Overview
Arsil dx is a combination product containing artesunate and mefloquine. Artesunate is an artemisinin derivative with rapid parasiticidal activity against *Plasmodium falciparum*. Mefloquine is a longer-acting antimalarial agent that also has blood schizonticidal activity.
## Primary Indications
Treatment of acute uncomplicated *Plasmodium falciparum* malaria in adults and children.
## Adult Dosing
* **Treatment Regimen:** A total of 3 doses are administered over 48 hours.
* **Day 1:** 4 mg/kg artesunate (maximum 200 mg) PLUS 20 mg/kg mefloquine (maximum 1000 mg) as a single dose.
* **Day 2:** 2 mg/kg artesunate (maximum 100 mg) as a single dose.
* **Day 3:** 2 mg/kg artesunate (maximum 100 mg) as a single dose.
## Pediatric Dosing
* **Treatment Regimen:** Dosing is weight-based as per adult regimen. Refer to specific product labeling or local guidelines for precise weight banding if available.
* **Day 1:** 4 mg/kg artesunate (maximum 200 mg) PLUS 20 mg/kg mefloquine (maximum 1000 mg) as a single dose.
* **Day 2:** 2 mg/kg artesunate (maximum 100 mg) as a single dose.
* **Day 3:** 2 mg/kg artesunate (maximum 100 mg) as a single dose.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustments are routinely recommended, but caution is advised.
* **Hepatic Impairment:** No specific dose adjustments are routinely recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to artesunate, mefloquine, or any excipients.
* Use in patients with severe malaria.
* Concurrent use with drugs that prolong the QT interval.
* Concurrent use with drugs that are strong CYP3A4 inhibitors.
* History of certain cardiac conditions (e.g., arrhythmias, structural heart disease, conduction disturbances).
* Concurrent use with other quinoline antimalarials (e.g., quinine, chloroquine, amodiaquine).
* Concurrent use with halofantrine.
## Adverse Effects
* **Common:** Headache, dizziness, nausea, vomiting, diarrhea, abdominal pain, cough, fatigue, myalgia, arthralgia, rash.
* **Serious:** Neuropsychiatric effects (e.g., anxiety, depression, confusion, hallucinations, psychosis, seizures), cardiac arrhythmias (including QT prolongation and Torsades de Pointes), hypersensitivity reactions, liver injury, cytopenias.
## Key Drug Interactions
* **CYP3A4 Substrates/Inhibitors:** Mefloquine is a CYP3A4 inhibitor and may increase plasma concentrations of drugs metabolized by this enzyme. Consider dose adjustments for narrow therapeutic index CYP3A4 substrates.
* **QT Prolonging Agents:** Concurrent use with other drugs known to prolong the QT interval (e.g., antiarrhythmics, certain antibiotics, antipsychotics) increases the risk of arrhythmias.
* **Antimalarials:** Avoid concurrent use with other quinoline antimalarials (e.g., quinine, chloroquine) and halofantrine due to increased risk of cardiotoxicity.
* **Rifampicin:** May decrease plasma concentrations of mefloquine.
* **Ketoconazole:** May increase plasma concentrations of mefloquine.
* **Vaccines:** Live attenuated vaccines should be avoided during treatment with mefloquine.
## Monitoring
* Monitor for signs and symptoms of neuropsychiatric adverse events.
* Monitor for cardiac adverse events, particularly in patients with risk factors.
* Monitor liver function tests periodically, especially with prolonged use or in patients with pre-existing liver disease.
* Monitor complete blood counts periodically.
## Clinical Pearls
* Arsil dx is intended for the treatment of uncomplicated *P. falciparum* malaria. Severe malaria requires parenteral treatment.
* Due to the risk of neuropsychiatric side effects, patients should be advised to report any unusual behavioral changes or psychiatric symptoms immediately.
* Mefloquine has a long half-life, and adverse effects may persist for weeks after discontinuation.
* The combination is typically administered as a complete 3-dose regimen over 48 hours.
* This combination may not be suitable for malaria prophylaxis in all populations due to the risk of side effects.
---
***Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and local guidelines for definitive patient care decisions.*
